Skip to main content

Table 1 Clinical-pathological characteristics of locally advanced gastric cancer patients with neoadjuvant chemotherapy according to the lymph node ratio

From: Lymph node ratio is a prospective prognostic indicator for locally advanced gastric cancer patients after neoadjuvant chemotherapy

Variables Total (n = 148) Low-LNR (n = 103) High-LNR (n = 45) P
Gender     0.146
 Male 122 88 (85.4%) 34 (75.6%)
 Female 26 15 (14.6%) 11 (24.4%)
Age     0.757
 < 65 y 111 78 (75.7%) 33 (73.3%)
 ≥ 65 y 37 25 (24.3%) 12 (26.7%)
Tumor location     0.620
 Upper stomach 94 68 (66.0%) 26 (57.8%)
 Middle stomach 19 12 (11.7%) 7 (15.6%)
 Lower stomach 35 23 (22.3%) 12 (26.7%)
NACT regimen     0.098
 FOLFOX 81 51 (49.5%) 30 (66.7%)
 SOX 55 45 (43.7%) 10 (22.2%)
 XELOX 7 4 (3.9%) 3 (6.7%)
 FLOT 5 3 (2.9%) 2 (4.4%)
NACT cycle     0.174
 < 3 73 47 (45.6%) 26 (57.8%)
 ≥ 3 75 56 (54.4%) 19 (42.2%)
Operation method     0.121
 Laparoscopic 80 60 (58.3%) 20 (44.4%)
 Open 68 43 (41.7%) 25 (55.6%)
Resection type     0.226
 Proximal 30 23 (22.3%) 7 (15.6%)
 Distal 21 17 (16.5%) 4 (8.9%)
 Total 97 63 (61.2%) 34 (75.6%)
Number of lymph node harvested   25.3 ± 9.5 21.3 ± 7.4 0.486
Histologic grade     .082
 Well 8 7 (6.8%) 1 (2.2%)
 Moderately 37 30 (29.1%) 7 (15.6%)
 Poorly 103 66 (64.1%) 37 (82.2%)
Margin status     0.287
 R0 134 95 (92.2%) 39 (86.7%)
 R1 14 8 (7.8%) 6 (13.3%)
TRG     .012
 0 5 5 (4.9%) 0 (0%)  
 1 15 14 (13.6%) 1 (2.2%)
 2 43 33 (32.0%) 10 (22.2%)
 3 85 51 (49.5%) 34 (75.6%)
ypT stage     .002
 0 5 5 (4.9%) 0 (0%)  
 1 15 15 (14.6%) 0 (0%)  
 2 15 13 (12.6%) 2 (4.4%)
 3 67 46 (44.7%) 21 (46.7%)
 4 46 24 (23.3%) 22 (48.9%)
Postoperative complications     0.787
 Yes 36 25 (24.3%) 10 (22.2%)
 No 113 78 (75.7%) 35 (77.8%)
Hospital stay     0.201
 ≤ 12 days 118 85 (82.5%) 33 (73.3%)
 > 12 days 30 18 (17.5%) 12 (26.7%)
Postoperative chemotherapy     0.696
 Yes 118 83 (80.6%) 35 (77.8%)
 No 30 20 (19.4%) 10 (22.2%)
  1. Abbreviations: LNR Lymph node ratio, NACT Neoadjuvant chemotherapy, TRG Tumor regression grade